As the U.S. economy reopens, engagement with healthcare providers and pharma manufacturers will vary significantly from person to person depending on their comfort level. This article provides insight on how engagement could affect product launches.
Ben Hohn
Advertisement
Articles by Ben Hohn
Judith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.
Pharmaceutical Executive
Three product launch trends driven by emerging biopharma.
Advertisement
Latest Updated Articles
Is the Tail Wagging the Dog in Drug Market Entry?January 13th 2020
Adapting Biopharma Launches in the COVID-19 LandscapeApril 7th 2020
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx Selling Medicines at Higher Prices Than Other Countries: Report
2
FDA Approves Wegovy HD Injectable Under Accelerated Approval
3
What Are the ‘Last Mile Issues’ Impacting Pharma?
4
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
5